Cardiovascular disease (CVD) mortality increased by 78%, rising from 72.4 to 128.7 per 100 000 (2017–2022), with the greatest ...

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight ...

BACKGROUND: Evaluation of whether dyspnea has a cardiac cause is essential. Guidelines from 2016 were reported to result in a ...

Using the Global Burden of Disease 2021 data, we analyzed the prevalence and disability‐adjusted life years, examining implications across demographics and geographic regions. In 2021, an estimated 54 ...

Guideline-directed medical therapies and guideline-directed nonpharmacological therapies improve quality of life and survival in patients with heart failure (HF), but eligible patients, particularly ...

Research studies in cardiovascular epidemiology assessing the relationship between a primary exposure and a health outcome must account for the presence of what are often called third variables, ...

Effective medical therapies for patients with PAD should be prescribed to prevent major adverse cardiovascular events and major adverse limb events for patients with PAD, including antiplatelet ...

BACKGROUND: Allograft arteriosclerosis, a significant cause of graft failure, is linked to the formation of tertiary lymphoid organs. T follicular helper (Tfh) cells are a vital subset of helper T ...

Intraoperative transesophageal echocardiography is used with increasing frequency in cardiac surgery for monitoring and diagnostic purposes. Recent data have shown the impact of improved outcomes in ...

A 20-year-old woman presented with AFM and cardiogenic shock (left ventricular ejection fraction, 10%) requiring venoarterial extracorporeal membrane oxygenation support. Endomyocardial biopsy ...

BACKGROUND: Penetrance and risk of ventricular arrhythmias (VAs) in arrhythmogenic right ventricular cardiomyopathy (ARVC) are increasingly recognized as being genotype specific. Therefore, ...

BACKGROUND: Myeloproliferative neoplasms (MPN) are a group of chronic leukemias that are associated with pulmonary hypertension (PH), which has been associated with increased risk adverse outcomes.